key: cord-0279749-sh154bmn
authors: Ramadan, Ahmed A.; Mayilsamy, Karthick; McGill, Andrew R.; Ghosh, Anandita; Giulianotti, Marc A.; Donow, Haley M.; Mohapatra, Shyam S.; Mohapatra, Subhra; Chandran, Bala; Deschenes, Robert J.; Roy, Arunava
title: Inhibition of SARS-CoV-2 spike protein palmitoylation reduces virus infectivity
date: 2021-10-08
journal: bioRxiv
DOI: 10.1101/2021.10.07.463402
sha: cbe8069301650cdd7d1dedc6d6bab9bbb7cba4b2
doc_id: 279749
cord_uid: sh154bmn

Spike glycoproteins of almost all enveloped viruses are known to undergo post-translational attachment of palmitic acid moieties. The precise role of such palmitoylation of the spike protein in membrane fusion and infection is not completely understood. Here, we report that palmitoylation of the first five cysteine residues of the c-terminal cysteine-rich domain of the SARS-CoV-2 spike are indispensable for infection and palmitoylation deficient spike mutants are defective in trimerization and subsequent membrane fusion. The DHHC9 palmitoyltransferase interacts with and palmitoylates the spike protein in the ER and Golgi, and knockdown of DHHC9 results in reduced fusion and infection of SARS-CoV-2. Two bis-piperazine backbone-based DHHC9 inhibitors inhibit SARS-CoV-2 spike protein palmitoylation and the resulting progeny virion particles released are defective in fusion and infection. This establishes these palmitoyltransferase inhibitors as potential new intervention strategies against SARS-CoV-2.

The last two decades have seen the emergence of three major coronavirus (CoV) 2 outbreaks. The first was the Severe Acute Respiratory Syndrome-CoV (SARS-CoV) in 3 2002, then Middle East Respiratory Syndrome-CoV (MERS-CoV) in 2012 and most 4 recently, the SARS-CoV-2 virus causing the COVID-19 pandemic. β-Coronaviruses are 5 enveloped, positive-stranded RNA viruses that express a spike protein on the surface 6 giving the virus the appearance of a crown or corona, in Latin. The SARS-CoV-2 spike 7 glycoprotein (S) is a 1273 amino acids type I membrane protein that binds to the ACE2 8 receptor on the host cell to initiate infection, viral uptake, and cell-cell fusion (1, 2) . 9 Structurally, the unprocessed S protein precursor consists of an N-terminal signal 10 sequence for endoplasmic reticulum (ER) insertion and a large ectodomain (ER luminal - 11 virion exterior) composed of glycosylation sites, a receptor binding domain (RBD), a that these novel compounds inhibit palmitoylation of SARS-CoV-2 spike proteins resulting 1 in reduced virus infectivity. 2 Here, we present our studies on the role of palmitoylation of the SARS-CoV-2 spike 3 protein using a pseudotyped luciferase lentivirus system as well as SARS-CoV-2 virus 4 infection. We employ a number of CRD cysteine mutants of the spike protein to evaluate 5 the propensity of different cysteine clusters to be palmitoylated. We then evaluate the role 6 of spike palmitoylation on trimerization, S1/S2 furin cleavage, transport through the 7 secretory pathway, release on mature virion particles, binding to the ACE2 receptor, cell- 8 cell syncytia formation and infection. We identify DHHC9 as a PAT palmitoylating the 9 SARS-CoV-2 spike protein and demonstrate its co-localization and physical interaction 10 with the spike protein in transfected cells as well in SARS-CoV-2 infected cells. Finally, 11 we extended our studies to include SARS-CoV-2-mNG (SARS-CoV-2 stably encoding 12 mNeonGreen) and show that PAT inhibitors also reduce SARS-CoV-2 infection and 13 syncytia formation. Together, these results establish DHHC9 as a potential target against 14 SARS-CoV-2 and identify lead compounds for the intervention of the SARS-CoV-2 15 lifecycle and infectivity. 16 

SARS-CoV-2 spike protein is palmitoylated on multiple sites. 18 Cysteines in close proximity to transmembrane helices have higher propensity to 19 be palmitoylated (35) . The C-terminal CRD of SARS-CoV-2 spike protein has 10 highly 20 conserved juxtamembrane cysteine residues, 9 of which were predicted to be potential 21 sites of palmitoylation by the palmitoylation prediction server at 22 http://csspalm.biocuckoo.org/online.php (36) (Fig. 1A) . To investigate the role of 23 palmitoylation at these 10 Cysteine residues, we grouped them into 4 clusters -C1 1 (C1235, 1236), C2 (C1240, C1241, 1243), C3 (C1247, 1248, 1250) and C4 (C1253, 2 1254), and mutated each cluster to serine (Fig. 1A) . We also generated a ∆C mutant in 3 which all 10 cysteines were mutated to serine. The Acyl-PEGyl Exchange Gel-Shift 4 (APEGS) Assay was used to assess the palmitoylation of wild-type (WT) and cysteine 5 mutant S proteins, which employs mPEG-maleimide alkylation to label palmitoylated 6 cysteine residues to study the effect of these mutations on the palmitoylation of the S 7 protein. After PEGylation, the samples were separated by SDS-PAGE and visualized by 8 chemiluminescence using a monoclonal antibody specific for the S2 fragment of the Spike 9 protein. The mPEG minus APEGS reactions served as a control and confirmed the 10 observed gel shifted palmitoylated bands were due to PEGylation at the available 11 cysteine residues. The C1, C2, and C4 cysteine clusters reduced palmitoylation 12 significantly, whereas the ∆C mutation led to undetectable levels of palmitoylation (Fig. 13 1B). Mutating the C3 cluster appears to be less important for palmitoylation (Fig. 1B) . 14 The S protein shifted to several higher molecular weight bands representing different 15 populations of the spike protein with varying degrees of palmitoylation (Fig. 1B) . GAPDH, 16 which is also known to undergo palmitoylation (37) was used as a positive control for the 17 APEGS reaction and as a loading control to show equal protein loading per well. 18 Next, we employed a luciferase reporter SARS-COV-2 spike pseudotyped 19 lentivirus system to study the effect of these cysteine cluster mutations on the cellular 20 entry and infectivity of the S protein by measuring the luciferase activity 48 h after 21 pseudovirus infection of HEK293T-ACE2 or Caco-2 cells (Fig. 1C ). Compared to S WT, 22 the ∆C mutant was highly defective in infection of HEK293T-ACE2 cells (Fig. 1D ). 23 Clusters C1 and C2 mutations were also defective in infection to levels similar to the ∆C 1 mutant (Fig. 1D ). In contrast, clusters C3 and C4 mutations had almost no diminution of 2 pseudovirus entry. Similar results were observed with Caco-2 cells which expresses ACE- 3 2 endogenously (Fig. 1E ). Together, these data indicate that the first five cysteine 4 residues of the SARS-CoV-2 spike protein CRD (C1235, 1236, 1240, 1241 and 1243) are 5 the most functionally important residues to be palmitoylated for infection of ACE-2 6 expressing cells. 7 Mutation of Cluster C2 (C1240, C1241, 1243) of S protein abrogates trimerization 8 Next, to investigate if the observed reduction in the infectivity of the C1, C2 and 9 ∆C mutant pseudotyped lentiviruses are due to defects in the intracellular processing of 10 the nascent S protein, we tested its trimerization and intracellular furin cleavage at the 11 S1/S2 site by resolving the WT and the mutant S proteins expressed in 293T cells on 12 native-PAGE. Relative band intensities of the three forms of the S protein -S2 fragment, 13 full length, and trimer were normalized to WT being 1.0. As shown in Fig. 2A and B, 14 compared to the WT protein, mutants C2 and ∆C were severely defective in trimer 15 formation. Spike protein trimerization is known to be essential for its membrane fusion 16 and thus, infection ability (38) . Furin mediated cleavage at the S1/S2 site of the spike 17 protein is a gain-of-function unique to SARS-CoV-2, which is absent in SARS-CoV and 18 other SARS-related coronaviruses (39) . There was no detectable difference in spike furin 19 cleavage between WT and the mutants ( Fig. 2A and B ). 20 Lentivirus based pseudotyped virus assembly and budding occurs at the host 21 plasma membrane. Therefore, we investigated the effect of the cysteine cluster mutations 22 on the transport of the S protein to the plasma membrane. For this, we performed surface 23 immunofluorescence assay (SIF) and immunostained the S protein on non-permeabilized 1 cells. We found that only the ∆C mutant exhibited moderate reduction in its surface 2 expression, while the rest of the cysteine cluster mutations had no measurable effect (Fig.   3 2C). This indicates that the reduced infectivity of the C1 and C2 mutant pseudotyped 4 lentivirus is not due to defects in their ability to be transported to the plasma membrane. 5 Next, we tested the effect of these mutants on the packaging and egress of the S- 6 pseudotyped lentivirus particles. For this, we collected cell-free S-pseudotyped lentivirus 7 supernatants and compared their egress by performing ELISA against the lentivirus 8 capsid protein, p24. Our results show that none of the cysteine cluster mutants had any 9 effect on the egress of the pseudotyped lentivirus (Fig. 2D) . However, the ∆C mutant 10 showed a moderate, but significant reduction, indicating that only mutating all 10 11 cysteines has a measurable effect on pseudotyped lentivirus egress. 12 The effect of spike palmitoylation on ACE2 receptor binding was examined by co- 13 immunoprecipitation. ACE2 was immunoreacted with anti-ACE2 antibody followed by 14 detection of spike by immunoblotting with anti-spike antibody. There appeared to be no 15 difference in ACE2 binding comparing WT to the cysteine cluster mutants (Fig. 2E ). 16 Together, these experiments establish that ∆C, and to a lesser extent C1 and C2 exhibit 17 reduced trimerization of the spike protein, whereas furin cleavage, cell surface 18 localization, pseudovirus egress, and ACE2 binding remains unaltered. 19 Mutating the CRD diminishes S protein mediated membrane fusion and syncytia 20 formation 21 CoV spike proteins play an indispensable role in the fusion between the viral 22 envelope and the target cell membrane, or between an infected cell and an uninfected 23 cell membrane (40, 41) . Both are essential steps in virus infection and entry, and in cell 1 to cell spread and pathogenesis. Therefore, we investigated the effect of the cysteine 2 cluster mutations on the fusogenic potential of the SARS-CoV-2 S protein. For this, we 3 transfected HEK293T-EGFP (HEK293T cells stably transfected with EGFP) with S WT or 4 its mutant plasmids. 293T-ACE2 cells were stained with a red cell tracker dye and 6 h 5 later, the two cells were mixed at 1:1 ratio, and co-cultured together. When the GFP+S 6 expressing cells and the ACE2 expressing red cells fuse and form a syncytium, it will 7 appear as yellow under a fluorescent microscope (Fig. 3A) . First, we compared S WT to 8 the ΔC mutant and observed that the palmitoylation deficient spike protein exhibited a 9 marked reduction in syncytia formation ( Fig. 3B and C ). Subsequently, we tested all the 10 cysteine cluster mutants and, consistent with our pseudovirus infection observations (Fig.   11 1D and E), we observed that C1 and C2 cluster mutations have the greatest effect on 12 syncytia formation ( Fig. 3D and E). C3 and C4 clusters had lower, but significant effects 13 on syncytia formation. These results collectively show that the first 5 cysteines of the 14 SARS-CoV-2 S CRD (C1235, 1236, 1240, 1241, 1243) play the most important role in 15 fusogenic activity. 16 Reducing DHHC9 levels decreases SARS-CoV-2 spike palmitoylation 17 Since palmitoylation of the S protein is an indispensable step for CoV infection, we 18 sought to identify the DHHC PAT responsible for palmitoylating the spike CRD. Gordan 19 et.al found that the SARS-CoV-2 spike protein interacts with DHHC5 and Golga7 (27) . 20 Golga7 has been previously identified as an accessory protein of DHHC9 and DHHC5 21 (42, 43) . We thus knocked down DHHC5 and DHHC9 individually using siRNA in 22 HEK293T cells and 72h later confirmed their knock down efficiencies using RT-PCR and 23 1 Interestingly, knock down of DHHC5 led to a 1.8-fold upregulation of DHHC9 (Fig. 4A ), 2 whereas knock down of DHHC9 did not affect DHHC5 expression. The change in mRNA 3 levels resulted in commensurate changes in protein levels (Fig. 4B ). To examine this 4 further, we measured mRNA levels of a panel of DHHC genes following knock down of 5 DHHC5 and DHHC9. Knock down of DHHC5 resulted in a compensatory upregulation 6 of DHHC9, 15 and 20 (Fig. S1 ). However, knock down of DHHC9 did not result in any 7 such compensatory upregulation of any other PAT (Fig. S1 ). 8 The APEGS assay was used to examine the palmitoylation of the spike protein 9 following knock down or DHHC5 or DHHC9. Reduction of DHHC9 significantly reduced 10 spike palmitoylation (Fig 4C) . In contrast, in DHHC5 knocked down cells S protein 11 palmitoylation increased, presumably due to the increase in DHHC9, but we cannot rule 12 out that DHHC15 and DHHC20 may also contribute since they are similarly upregulated 13 in a DHHC5 knockdown (Fig. S1 ). As expected, palmitoylation of GAPDH was unaffected 14 upon knockdown of both DHHC5 or DHHC9 (44) (Fig 4C, lower pane). 15 To evaluate the effect of DHHC5 and DHHC9 down regulation on the ability of S 16 protein pseudotyped lentivirus to infect ACE2 bearing cells, we generated lentivirus 17 particles from cells in which DHHC5 and 9 levels have been knock down. Reduction of 18 DHHC9, but not DHHC5, resulted in a significant reduction in infection of HEK293T-ACE2 19 cells (Fig. 4D ). In contrast, knock down DHHC9 or DHHC5 in the HEK293T-ACE2 cells 20 had no effect on the infection by pseudovirus derived from untreated cells (Fig. 4E) . Thus, 21 S protein palmitoylation is required for infection of HEK293T-ACE2 recipient cells, but not 22 for any downstream event following infection. We next tested if syncytia formation 23 requires DHHC5 or DHHC9. As seen in Fig. 4F and G, knock down of DHHC9, but not 1 DHHC5, resulted in significantly reduced syncytial formation.

2 DHHC9 co-localizes and interacts with the SARS-CoV-2 spike protein both in 3 transfected and infected cells 4 To determine whether DHHC9 interacts with the SARS-CoV-2 spike protein, we 5 performed a Co-IP experiment with FLAG tagged DHHC9 or its catalytic mutant, DHHA9 6 Mut, in HEK293T cells co-transfected with the spike protein. DHHC9 and the spike protein 7 physically interact and the interaction was not dependent on the palmitoyltransferase 8 activity of DHHC9 (Fig. 5A ). In contrast, a similar Co-IP experiment with Myc-tagged 9 Golga7 failed to detect an interaction with the spike protein (Fig. 5B ). 10 Next, to examine whether the spike protein interacts with DHHC9 in infected cells, 11 we performed immunofluorescence experiments in Vero-E6-ACE2 cells infected with 12 SARS-CoV-2 for 48 h. Co-localization (yellow) with the endoplasmic reticulum marker, 13 Calnexin and the cis-Golgi marker, GM130 indicates that the S protein localizes to both 14 the ER and the Golgi apparatus (Fig. 5C ). Similar observations were made in HEK293T 15 cells transfected with FLAG-DHHC9, Myc-Golga7 or the spike protein, where all of these 16 proteins were found to localize to the ER and the Golgi network (Fig. S2A ). Following this, 17 we performed co-localization experiments between the spike protein and DHHC5 and 9 18 in SARS-CoV-2 infected Caco-2 cells (Fig. 5D ). In agreement with previous observations 19 (44, 45) , we observed DHHC5 to be localized predominantly on the cell surface, but in 20 addition, some DHHC5 could be observed at other intracellular locations (Fig. 5D ). 21 Because the S protein is primarily localized to the ER and the Golgi, we did not observe 22 significant co-localization between S and DHHC5 (Fig. 5D , upper panel). However, under 23 similar conditions, DHHC9 extensively co-localized with spike protein (Fig. 5D , lower 1 panel). To further confirm the spike protein's co-localization with DHHC9 and to exclude 2 the possible non-specific staining due to the DHHC9 antibody, we performed similar co- 3 localization experiments in HEK293T cells transfected with FLAG DHHC9 and Myc- 4 tagged Golga7. Significant co-localization was observed between DHHC9 and the spike 5 protein (Fig. 5E, top panel) . Myc Golga7, also co-localized with the spike protein, albeit 6 to a lesser degree (Fig. 5E , bottom panel). 7 The proximity ligation assay (PLA) provides a better method to assess direct 8 interactions (<40nm) between proteins in cells (46) . When PLA was performed, we 9 observed robust interactions between the spike protein and FLAG DHHC9 (Fig. 5F ). We 10 also performed immunofluorescence against Calnexin and GM130 in the same 11 experiment and found that the PLA signal between the S protein and DHHC9 localizes 12 partially to the Golgi apparatus, but almost entirely to the ER network ( Fig. 5F , arrows). 13 This suggests that palmitoylation of spike occurs primarily in the ER and secondarily in 14 the ERGIC, as Calnexin is also found in the ERGIC (47, 48) . In a similar experiment, 15 where PLA was performed between the spike protein and Golga7, we failed to detect a 16 significant PLA signal, indicating again that spike and Golga7 do not directly interact with 17 each other (Fig. 5G ). The specificity of the PLA signal was confirmed by isotype IgG 18 controlled PLA reaction which did not produce any signal (Fig. S2B ).

20 dependent palmitoylation of spike protein 21 Having established that DHHC9 plays a major role in the palmitoylation of the was not measurably reduced after knockdown of DHHC5 or DHHC9 (Fig. 6A , B and S3). 10 However, at 48 and 72 h post-infection, the mNeonGreen signal in the DHHC9 knocked 11 down cells reduced significantly. We reason that, as the cells were infected with SARS- 12 CoV-2-mNG harvested from WT Vero-E6 cells, the S protein on these virus particles were 13 efficiently palmitoylated and knock down of the respective PATs in the recipient Caco-2 14 cells had Having identified DHHC9 as a SARS-CoV-2 spike protein palmitoylating enzyme, 3 we investigated whether inhibiting DHHC9 would inhibit SARS-CoV-2 infection. The 4 availability of validated and specific PAT inhibitors are fairly limited (50). 2-bromopalmitate 5 (2-BP), the most widely used PAT inhibitor promiscuously inhibit a wide range of enzyme 6 utilizing active site cysteine residues (32, (51) (52) (53) . Previously, using a scaffold ranking 7 approach to screen for novel inhibitors of the yeast homolog of DHHC9, members of our 8 group identified a number of bis-piperazine backbone based compounds (34) . Two leads 9 from this study, compounds 13 and 25, inhibited palmitoylation at low micromolar 10 concentrations. Compound 13 has the lead functional group, 2-(3,5-bis-11 trifluoromethylphenyl)-ethyl, at positions R1 and R3, while compound 25 has 4-tert-butyl- 12 cyclohexyl-methyl at the R1 position and 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl at 13 position R3 (Fig. 7A ). We evaluated the palmitoylation inhibitory potential of compounds 14 13 and 25 against the SARS-CoV-2 spike protein. 15 The compounds were first tested for toxicity on HEK293T and Caco-2 cells and 16 found to have no observable toxicity at concentrations below 3µM ( Fig. 7B and C, 17 respectively). We next examined whether compounds 13 and 25 inhibited the SARS-CoV- 18 2 spike protein palmitoylation using APEGS assay. Compared to the vehicle control, 19 compounds 13 and 25 (3µM) reduced palmitoylation of the spike protein in HEK293T cells 20 by 37% and 44% respectively (Fig. 7D ). The non-specific PAT inhibitor, 2-BP, also 21 inhibited spike palmitoylation, but required 10µM concentration. In the same experiment, 22 we found that GAPDH palmitoylation is reduced by the non-specific inhibitor, 2-BP, but 23 not by compounds 13 and 25 ( Fig. 7D) , consistent with the specificity previously observed 1 for these compounds (34). 2 We next examined the effect of these palmitoyltransferase inhibitors on the cellular 3 entry and infectivity of SARS-COV-2 spike pseudotyped lentivirus on HEK293T-ACE2 4 cells. First, we treated the recipient HEK293T-ACE2 with inhibitors and found that there 5 was no reduction in luciferase signal upon treatment with compounds 13 and 25 (Fig. 7E ). 6 However, 2-BP caused a significant reduction in pseudovirus infection in this experiment, 7 implying that it interferes with lentivirus endocytosis (Fig. 7E ). This also signifies that 8 compounds 13 and 25 do not affect any step downstream of infection. In a second series 9 of experiments, HEK293T cells were treated with compounds 13, 25 or 2-BP and 10 pseudovirus produced from these cells were tested for their ability to infect untreated 11 HEK293T-ACE2 cells. In this case, we observed a significant reduction in the luciferase 12 signal (Fig. 7F ) indicating that inhibition of spike palmitoylation resulted in a pseudovirus 13 with reduced ability to infect cells. Under similar conditions, 2-BP also reduced luciferase 14 signal significantly. We also found that compounds 13 and 25 do not reduce the quantity 15 of pseudovirus released from the producer cells, indicating that there is no measurable 16 effect on lentivirus packaging and egress (Fig. 7G ). Furthermore, we observed that 17 inhibition of spike palmitoylation by compounds 13 and 25 reduces its fusogenicity in a 18 syncytia formation assay. Treatment with compound 13 (1µM and 3µM) resulted in a 58% 19 and 60% reduction in syncytia formation, respectively. Compound 25 (1µM and 3µM) 20 similarly reduced syncytia formation by 45% and 50%, respectively ( Fig. 7H and I). 21 

We tested the effect of these palmitoyltransferase inhibitors on SARS-CoV-2 1 infection using the SARS-CoV-2-mNG. Caco-2 cells pretreated with compounds 13, 25, 2 or 2-BP and infected with SARS-CoV-2-mNG exhibited dose dependent reduction in 3 mNeonGreen signal after 72 h of infection (Fig. 8A, B and S4 ). The size of the syncytia 4 were also reduced in the inhibitor treated cells compared to the control vehicle treated 5 cells (Fig. 8A ). This indicates that compounds 13 and 25 effectively inhibits SARS-CoV-2 6 spike protein palmitoylation causing a reduction in the infection competent virus released 7 to subsequently infect neighboring cells. 8 Next, virus containing supernatants were collected 72 h after SARS-CoV-2 9 infection of Caco-2 cells pre-treated with the inhibitors and used to infect Vero-E6 ACE2 10 cells. After 24 h, infection was quantitated by measuring the appearance of the SARS- 11 CoV-2 N gene by real-time RT-PCR. SARS-CoV-2 virus isolated from Caco-2 cells 12 treated with compounds 13 and 25 resulted in a 60% and 76% reduction viral infection of 13 Vero-E6 cells (Fig. 8C ). 14 

In this study, we demonstrate that the SARS-CoV-2 spike protein is palmitoylated 16 on a cluster of conserved cysteines residues on the cytosolic domains of the SARS-CoV- 17 2 spike protein. Mutating all 10 cysteine residues to serine (∆C) eliminates all detectable 18 palmitoylation, but mutating individual clusters of cysteines suggests that not all cysteine 19 residues are palmitoylated equivalently. For example, mutating clusters C1 (C1235, 20 C1236), C2 (C1240, C1241, C1243), and C4 (C1253, C1254) significantly reduces, but 21 does not eliminate spike palmitoylation. In contrast, spike palmitoylation is unaffected by 22 mutating the C3 (C1248, C1249, C1250) cluster. Individual cysteine clusters are also 23 functionally different. Mutating C1 and C2 clusters reduce infection of ACE-2 expressing 1 cells to the same extent as ∆C, indicating that palmitoylation of the juxtamembrane 2 cysteines are the most important for infection. Mutating the C3 cluster does not reduce 3 palmitoylation or influence infection. Interestingly, mutating the C4 cluster reduces overall 4 palmitoylation, but does not reduce infection suggesting that palmitoylation of the C4 5 cysteines may have other roles in the viral life cycle. 6 Palmitoylation of SARS-CoV-2 spike occurs in the ER and Golgi and results in 7 partitioning into detergent resistant, cholesterol and sphingolipid rich membrane 8 microdomains (26) . In contrast, palmitoylation defective spike is localized in detergent 9 soluble membrane fractions and results in 35% less spike on the cell surface. We also 10 find that the ∆C mutant of the spike protein decreases surface expression by 40% and 11 taken together, these results show that palmitoylation is important, but not essential for 12 the surface expression of the spike protein.

The spike protein appears to be able to 13 access alternate trafficking routes depending on palmitoylation. We have also shown that 14 palmitoylation is not required for ACE2 receptor binding. However, despite being capable 15 of binding ACE2 and a modest decrease in membrane expression, virus harboring non- 16 palmitoylated spike fail to infect host cells. One reason could be that membrane fusion 17 depends on surface density of spike proteins (54) . Palmitoylation dependent clustering of 18 the spike protein in infected cell lipid rafts could increase spike density on the membrane 19 to support membrane fusion. Alternatively, palmitoylation of spike may play a more direct 20 role in membrane fusion. 21 Since the palmitoylation sites of the SARS-CoV spike protein CRDs are in the 22 vicinity of the membrane bilayer, it is likely that the cytoplasmic tail folds back creating a 23 membrane anchor. The potential to palmitoylate up to 10 cysteine residues would create 1 a strong membrane anchor for the endodomains of the spike protein. While it is possible 2 that changes in the spike protein endodomain via palmitoylation or mutation of the 3 cysteine residues might destabilize the spike protein resulting in its proteasomal 4 clearance, we do not think this is the case. First, we find that the wild-type spike protein 5 and its palmitoylation defective mutants are expressed at approximately the same levels, 6 and, traffic to the plasma membrane and bind to ACE2 at the same levels. However, we 7 observed that the ∆C and C2 cysteine mutants results in a decrease in spike protein mechanisms likely results in the failure of non-palmitoylated spike proteins to carry out 1 efficient membrane fusion. 2 S-acylation of viral proteins requires the host cell palmitoylation machinery that, 3 depending on the cell type, consists of up to 23 individual DHHC PAT genes. Identification 4 of the DHHC protein or proteins that palmitoylate the SARS-CoV-2 spike has begun to 5 emerge from several lines of investigation. First, a comprehensive interactome study 6 uncovered an interaction between the SARS-CoV-2 spike protein and Golga7, an 7 auxiliary protein for DHHC5, DHHC9, and possible additional DHHC proteins (27) . All 8 animal reservoirs of coronaviruses express both DHHC9 and DHHC20 (59), and 9 observations from the knockdown and overexpression of DHHC8, 9, and 20 further 10 implicate these PATs in the palmitoylation of SARS-CoV-2 spike protein (26) . We used 11 several approaches to show that DHHC9 plays a major role in palmitoylating the SARS- 12 CoV-2 spike protein. Co-localization and proximity ligation studies confirm that both, the 13 spike protein and DHHC9, occupy the same spatial compartments inside the cell and they 14 physically interacts with each other in the ER, Golgi and the ERGIC. Knockdown of 15 DHHC9 resulted in a decrease in spike protein palmitoylation, pseudovirus fusion, 16 syncytia formation, and a 55% and 80% reduction of SARS- 4 Our work and that of several other groups have led to the suggestion that inhibitors 5 of palmitoylation may be developed into a new class of antivirals (27, 30, 31) . To do so 6 will require identification of high affinity, specific inhibitors of DHHC PATs. This has 7 proved to be difficult. Commonly used inhibitors such as 2-bromopalmitte show little 8 specificity, hitting a wide range of thiol containing enzymes (32) . We previously developed 9 a high throughput palmitoylation assay and used it to screen a chemical library consisting 10 of 68 unique scaffolds and 30 million unique structures for inhibition of the yeast ortholog 11 of DHHC9 (34) . Two compounds based on a bis-piperazine backbone (compounds 13 12 and 25) were selected to be tested for inhibition of SARS-CoV-2 spike palmitoylation and 13 viral infection. We found that both compounds decreased spike protein palmitoylation, 14 pseudovirus infection and syncytia formation. Further, experiments on SARS-CoV-2 15 infection established the robust inhibitory effect of compounds 13 and 25 on progeny 16 virion formation. Interestingly, the amino acid sequence of the core domain of DHHC9 is 17 highly homologous to that of DHHC20 (59) . Therefore, it will be interesting to evaluate in 18 future studies if compounds 13 and 25 inhibit DHHC20 in addition to DHHC9. Because 19 the spike protein of viruses with zoonotic potential are often found to be palmitoylated by 20 a similar set of PATs (59), compounds 13 and 25 may also have potential anti-viral effect 21 on other existing or emerging viruses. Lentivirus was produced by transfecting 10 6 HEK293T cells on a 60 mm plate with pMDL, 8 pRev and pVSVG using CalPhos mammalian transfection kit (TaKaRa Clontech). Next 9 day, fresh media was added, then two days after transfection, the supernatant was 10 harvested, and filtered 0.45-μm filter to remove cell debris. The filtered supernatant 11 containing lentiviral vectors was used to transduce HEK293T cells seeded one day 12 before. 48 hours later, the cells were selected in DMEM supplemented with 2 μg/ml 13 puromycin for one week. The puromycin-resistant population of HEK293T-EGFP cells 14 was found to constitutively express EGFP by fluorescent microscopy. These HEK293T- 15 EGFP cells were used as donor cells in syncytium formation assays. Caco-2 (human 16 colon epithelial cells) cells, obtained from ATCC (HTB-37), were grown in Minimum 17 Essential Medium (Gibco # 11095080.) media supplemented with 20% fetal bovine serum 18 (Sigma, #F4135), Penicillin-Streptomycin (Gibco, #15140148), 1x non-essential amino 19 acid solution (Cytiva, SH3023801) and 10 mM sodium pyruvate (Gibco, # 11360070). All 20 cell lines were incubated at 37°C in the presence of 5% CO2. For pseudo-typed virus production, HEK293T cells were transfected using the 11 CalPhos mammalian transfection kit (TaKaRa Clontech) according to the manufacturer's 12 instructions. For the syncytia formation assay, HEK293T-GFP cells were transiently 13 transfected with wild-type and mutant spike plasmids using TransIT-X2 transfection 14 reagent (Mirus #MIR 6000) according to the manufacturer's instructions, and fresh media 15 was added after 6 hours. 16 17 The assay was done as previously described (62) Whole cell lysates were prepared using RIPA Lysis Buffer (Thermo scientific 10 #89900) supplemented with a protease inhibitor cocktail (Roche# 11836170001) for 30 11 min on ice and then sonicated three times at an amplitude setting of 50 with pulses of 15s 12 on and 15s off on a Qsonica Q700 sonicator. The lysates were clarified by centrifugation 13 at 13,000 X g for 15 min at 4°C. Protein concentrations were estimated using Pierce BCA 14 protein assay kit (Thermo scientific #23225) as per manufactural instructions and equal 15 concentration of proteins resolved appropriate SDS PAGE gels. SDS polyacrylamide gels 16 were transferred on Nitrocelluose membranes (GE) by Wet transfer BioRad System at 17 300 Amps for 90 min at 4°C, membranes were blocked with 5% non-fat milk for 1 hour at 18 room temperature (RT) and were incubated with primary antibodies diluted in PBST 19 solution at 4°C overnight. All primary antibodies used in this study are listed in table T3. 20 Membranes were washed with PBST for 5 minutes, 3 times and subsequently incubated 21 with appropriate secondary antibodies. Blots were then washed three times with PBST 22 for 5 minutes each wash. The immunoreactive bands were developed using Super Signal 23 1 Femto chemiluminescent substrate (Thermo scientific #34095) depending on the signal 2 strength. Blots were developed on a Bio-Rad ChemiDoc XRS+ System. 3 Co-immunoprecipitation (Co-IP) 4 Whole cell lysates were prepared using Pierce IP Lysis Buffer (Pierce #87788) 5 supplemented with a protease inhibitor cocktail for 30 min on ice and then sonicated three 6 times at an amplitude setting of 30 with pulses of 15s on and 15s off on a Qsonica Q700 7 sonicator at 4°C. The lysates were then clarified by centrifugation at 13,000 X g for 15 8 minutes at 4°C and protein concentrations estimated by BCA reaction. For IP, 300 µg of 9 the prepared lysate was incubated with the appropriate antibody (3 µg) and pulled down 10 using protein A Sepharose 6MB (GE healthcare # 17-0469-01). All primary antibodies 11 used in this study are listed in table T3. The immunoprecipitates were washed three times 12 with lysis buffer at 4°C and resolved on SDS-PAGE followed by immunoblotting. 13 Wherever mentioned, light-chain-specific secondary antibodies were used to avoid heavy 14 chain bands in WB of co-IP experiments. 15 16 To assess the level of protein S-palmitoylation on the SARS-CoV2 spike protein 17 we did APEGS as described previously (63) . In brief, HEK293T cells transfected with 18 appropriate plasmids were lysed with the following buffer, 4% SDS, 5 mM EDTA, in 19 triethanolamine buffer (TEA) pH 7.3 with protease inhibitors and PMSF (5 mM). After 20 centrifugation at 20,000 × g for 15 min, proteins in the supernatant were reduced with 25 21 mM tris(2-carboxyethyl)phosphine (TCEP, Thermo Scientific, #20490) for 1 hour at RT, 22 and free cysteine residues were blocked with 20 mM N-ethyl maleimide (NEM, Sigma 23 #E3876) for 3 hours at RT. To terminate the NEM reaction and wash any residual NEM, 1 pre-chilled methanol: chloroform: H2O (4:1.5:3) was added to the reaction. This wash 2 was repeated three times. Next, the proteins were re-suspended in TEA with 4% SDS 3 and 5 mM EDTA, then incubated in buffer containing 0.2% Triton X-100, 5 mM EDTA, 1 4 M NH2OH, pH 7.0 for 1 hour at RT to cleave palmitoylation thioester bonds. The reaction 5 was terminated as above, and proteins re-suspended in TEA with 4% SDS were 6 PEGylated with 1.33 mM mPEGs (10 kDa, Sunbright, #ME050) for 2 hours at RT to label 7 palmitoylation sites. The reaction was terminated as above; proteins were re-suspended 8 with TEA buffer with 4% SDS. Protein concentration was measured by BCA protein 9 assay. Thereafter, SDS PAGE sample buffer was added and samples were heated at 70 10 °C for 10 minutes and run on a 7.5% gel for Spike and 12% for GAPDH. 3. Mobile phases for LCMS analysis were HPLC grade or LCMS grade obtained from 10 Sigma Aldrich and Fisher Scientific. The mobile phases consisted of a mixture of LCMS 11 grade acetonitrile and water (both with 0.1% formic acid for a pH of 2.7). The initial setting 12 for analysis was at 5% acetonitrile (v/v), linearly increasing to 95% acetonitrile over 6 13 minutes. The gradient was then held at 95% acetonitrile for 2 minutes until linearly 14 decreasing to 5% over 1 minute. From there, the gradient was held until stop for an 15 additional 3 minutes. The total run time was equal to 12 minutes. The total flow rate was 16 set to 0.5 mL/minute. The column oven and flow cell temperature for the diode array 17 detector were set at 40°C. The auto sampler temperature was held at 15°C. 10 μl was 18 injected for analysis. 8 Cellular toxicity assay 9 The XTT Cell Proliferation Kit II (Roche # 11465015001) was used for assessing 10 cellular toxicity following manufacturer's instruction. DMSO was used as a vehicle for all 11 compounds and appropriate dilution of DMSO only was used as a control. 12 Gene Silencing 13 Genes were silenced using siRNAs obtained from IDT, DHHC5 (IDTDNA 14 #290128941) and DHHC9 (IDTDNA #290128950). For each gene, we used a 15 combination of three siRNAs. HEK293T cells were seeded on 24 well plate 24 h before 16 transfection. Transfection of these siRNAs was done using TransIT-X2 (Mirus #MIR 6000) 17 according to the manufacturer's instructions. Silencing efficacy was checked using qPCR 18 using SYBR Green real-time reagents (Invitrogen # 4367659) and immunoblotting. 19 RNA extraction and RT-qPCR 20 Total RNA was isolated using the RNeasy minikit (Qiagen #74106) following 21 manufacturer's instructions. On-column DNase digestion was performed by using an 22 RNase-free DNase set (Qiagen #79254). The extracted RNA concentration was 23 estimated using a NanoDrop spectrophotometer (Thermo Scientific), and 1 μg RNA was Immunofluorescence assay (IFA) and Proximity Ligation Assay (PLA) 10 Cells were grown on eight chamber glass slides, and treated as described in the 11 results. After appropriate incubations, the cells were fixed using 4% paraformaldehyde 12 for 15 min, and permeabilized with 0.2% Triton X-100 in PBS for 20 min. The slides were 13 then washed, blocked with Image-iT FX signal enhancer (Invitrogen #I36933) for 30 14 minutes at 37°C and incubated with primary antibodies for 1 h at 37°C. All primary 15 antibodies used in this study are listed in table T3. After this, the slides were washed three 16 times in PBS and incubated with corresponding fluorescent dye-conjugated secondary 17 antibodies for 30 minutes at 37°C. PLA was performed according to the manufacturer's All SARS-CoV-2 infections were performed using the same passage 3 SARS-CoV- 6 2 or SARS-CoV-2-mNG virus stocks. Caco-2 cells seeded to a confluency of 70 to 80%, 7 were washed twice in warm serum-free medium and inoculated with the indicated MOI of 8 the appropriate virus, diluted in serum-free medium (5 ml for T75; 2 ml for T25; 1 ml for 9 6-well plates). Two hours after inoculation cells were washed with complete medium and 10 infection was allowed to proceed for the indicated time points in DMEM supplemented 11 with 2.5% FBS. After infection, media with respective drugs were added and incubated 12 for 72 h. Images were quantified using ImageJ. 13 Drug treatments 14 For drug treatment, cells were treated with indicated concentrations of 2-BP 15 (Sigma, #238422) or compounds 13 and 25 dissolved in DMSO, 12 h prior to infection. 16 Post-infection, cells were continued to be incubated in presence of the respective drugs 17 for the indicated time. 18 Statistical analysis and reproducibility 19 Statistical analysis was performed using GraphPad Prism 9 (San Diego, CA). For 20 two groups, means were compared by two-tailed unpaired Student's t test. For multiple 21 groups, analysis was done by one-way ANOVA with Dunnett correction for multiple 22 comparisons. P value of < 0.05 was considered statistically significant. Specific statistical 23 test results are indicated in each figure: *= p < 0.05; **= p < 0.01; ***= p < 0.001; ****= p 1 <0.0001. immunoprecipitated and the presence of S protein was assayed by immunoblot using 14 antibody specific to the S1 subunit. ACE2 immunoprecipitation was also confirmed. Inputs 15 were quantitated by immunoblot (bottom panels). 16 

cell-cell fusion ability by measuring the pixel density of the observed syncytia. D-E. Same 1 as in B and C, but, with cysteine cluster mutants of the S protein. 13 immunostained with anti-FLAG or anti-Myc antibodies together with anti-spike antibodies, 14 to show co-localization of transfected spike with exogenous DHHC9 and Golga7. F. 15 Proximity ligation assay (PLA) to detect the physical proximity between the spike protein 16 and FLAG-DHHC9. Experiment was performed as in (D), and PLA was performed with 17 the indicated antibodies followed by immunofluorescence (IFA) against either GM130 or 18 Calnexin to visualize the sub-cellular localization of the detected PLA spots. G. PLA to 19 detect the physical proximity between the spike protein and Myc-Golga7. Experiment 20 same as in F. 

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Viral targets for vaccines against COVID-19

Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains

Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains

S-acylation of SARS-CoV-2 Spike Protein: Mechanistic Dissection, In Vitro Reconstitution and Role in Viral Infectivity

Palmitoylation of SARS-CoV-2 S protein is essential for viral infectivity

Dynamic protein palmitoylation in cellular signaling

Protein palmitoylation by a family of DHHC protein S-acyltransferases

Structure and function of DHHC protein S-acyltransferases

Identification of a Ras palmitoyltransferase in Saccharomyces cerevisiae

The yeast DHHC cysteine-rich domain protein Akr1p is a palmitoyl transferase

SwissPalm 2: Protein S-Palmitoylation Database

Palmitoylation: policing protein stability and traffic

Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies

Palmitoylation of virus proteins

Palmitoylations on murine coronavirus spike proteins are essential for virion assembly and infectivity

Replication of murine coronavirus requires multiple cysteines in the endodomain of spike protein

Palmitoylation of the cysteine-rich endodomain of the SARS-coronavirus spike glycoprotein is important for spike-mediated cell fusion

Palmitoylation of SARS-CoV S protein is necessary for partitioning into detergent-resistant membranes and cell-cell fusion but not interaction with M protein

The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens

The intracellular sites of early replication and budding of SARScoronavirus

Intracellular targeting signals contribute to localization of coronavirus spike proteins near the virus assembly site

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Cellular mechanisms of alpha herpesvirus egress: live cell fluorescence microscopy of pseudorabies virus exocytosis

Sacylation controls SARS-CoV-2 membrane lipid organization and enhances infectivity

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation

Fatty Acid Synthase inhibition prevents palmitoylation of SARS-CoV2

Spike Protein and improves survival of mice infected with murine hepatitis virus

A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19

Toward the identification of ZDHHC enzymes required for palmitoylation of viral protein as potential drug targets

Targeting protein palmitoylation: selective inhibitors and implications in disease

Identification of Protein Palmitoylation Inhibitors from a Scaffold Ranking Library

Stochastic palmitoylation of accessible cysteines in membrane proteins revealed by native mass spectrometry

CSS-Palm 2.0: an updated software for palmitoylation sites prediction

Submicromolar concentrations of palmitoyl-CoA specifically thioesterify cysteine 244 in glyceraldehyde-3-phosphate dehydrogenase inhibiting enzyme activity: a novel mechanism potentially underlying fatty acid induced insulin resistance

Distinct conformational states of SARS-CoV-2 spike protein

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

How the coronavirus infects cells -and why Delta is so dangerous

DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H-and N-Ras

Identification and characterization of GCP16, a novel acylated Golgi protein that interacts with GCP170

Akimzhanov AM, Boehning D. 2020. DHHC5 Mediates beta-Adrenergic Signaling in Cardiomyocytes by Targeting Galpha Proteins

S-acylated Golga7b stabilises DHHC5 at the plasma membrane to regulate cell adhesion

Protein detection using proximity-dependent DNA ligation assays

Calnexin is associated with and induced by overexpressed human complement protein C2

The subcellular distribution of calnexin is mediated by PACS-2

An Infectious cDNA Clone of SARS-CoV-2

Palmitoyl acyltransferase assays and inhibitors (Review)

Bardes ES. 1992. 2-Bromopalmitoyl-CoA and 2-bromopalmitate: promiscuous inhibitors of membrane-bound enzymes

Specific inhibition of mitochondrial fatty acid oxidation by 2-bromopalmitate and its coenzyme A and carnitine esters

2-Bromopalmitate reduces protein deacylation by inhibition of acyl-protein thioesterase enzymatic activities

Architecture of the influenza hemagglutinin membrane fusion site

Amino acid substitutions within the leucine zipper domain of the murine coronavirus spike protein cause defects in oligomerization and the ability to induce cell-to-cell fusion

Coronavirus-induced membrane fusion requires the cysteine-rich domain in the spike protein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Role of spike protein endodomains in regulating coronavirus entry

S-Acylation of Proteins of Coronavirus and Influenza Virus: Conservation of Acylation Sites in Animal Viruses and DHHC Acyltransferases in Their Animal Reservoirs

Palmitoylation of SARS-CoV-2 S protein is critical for S-mediated syncytia formation and virus entry

A thirdgeneration lentivirus vector with a conditional packaging system

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Mass-Tag Labeling Using Acyl-PEG Exchange for the Determination of Endogenous Protein S-Fatty Acylation

siRNA Knockdown of Mammalian zDHHCs and Validation of mRNA Expression by RT-qPCR

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

We gratefully thank the following sources for reagents: The SARS-Related Coronavirus